- July 2016
Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
- June 2016
Key advances in clinical trials.
- May 2016
Mark Lemmon on the underlying biochemistry of cancer.
- April 2016
Roger Stupp on using alternating electric fields as treatment.
- March 2016
Charlotte Vrinten on public perception of deaths from cancer.
- February 2016
Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
- December 2015/January 2016
Nazneen Rahman on germline genetic screening in ovarian cancer.
- November 2015
Caroline Robert on new developments in immunotherapy.
- October 2015
Milena Sant on the latest results from the EUROCARE study.
- September 2015
The science behind the IARC code that could reduce cancer in Europe.
- July/August 2015
Thomas Helleday on an exciting new class of drug, MTH1 inhibitors.
- June 2015
Lesley Seymour and Jan Bogaerts on the future of RECIST.
- May 2015
Paul Workman on strategies for overcoming resistance to new drugs.
- April 2015
Highlights from the TAT Congress in Paris.
- March 2015
Christopher Wild on the exposome, a measure of environmental exposure.
EJC News Focus – July/August 2013
Good times and bad for clinical trials research
Functional imaging and other new technologies are revolutionising the landscape for cancer research. The knowledge imparted by these techniques – from genetics, epigenetics, proteomics and so on – should mean that we're entering a new phase in our understanding and therefore treatment of the disease.
Yet many of the same old obstacles between lab and clinic remain. Clinical trials research is still dogged by regulatory issues, funding is a perennial problem, agreement on data protection has yet to be reached.
EORTC President Roger Stupp calls for the patient's point of view to move centre stage. While rarified discussions and debates take place, patients are waiting for clinical trials to be set up and for results to be integrated into clinical practice, he says. Here, he tells Helen Saul that speedy activation of trials is needed, as is funding for academic trials and, overall, a common sense approach which would allow the questions most relevant to patients, to be addressed.